IQVIA Holdings Inc. (IQV) EV/Assets Ratio: 1.51x
Is IQVIA Holdings Inc.’s EV/Assets ratio high or low?
IQVIA Holdings Inc.'s EV/Assets ratio of 1.51x is 24% below its 5-year average of 1.99x, near the low end of its 5-year range (1.36x–2.76x).
As of Sunday, June 14, 2026. 6.39% below its 12-month average of 1.61x.
IQV EV/Assets Ratio Chart
IQV Average EV/Assets Ratio Chart
IQV Current vs Average EV/Assets Ratio Chart
IQV EV/Assets Ratio Metrics
EV/ASSETS RATIO
1.51x
EV/ASSETS RATIO AVG TTM
1.61x
EV/ASSETS RATIO AVG 3Y
1.83x
EV/ASSETS RATIO AVG 5Y
1.99x
EV/ASSETS RATIO AVG 10Y
1.87x
EV/ASSETS RATIO AVG 15Y
N/A
EV/ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.39%
CURRENT VS 3Y AVG
-17.41%
CURRENT VS 5Y AVG
-24.21%
CURRENT VS 10Y AVG
-19.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
IQV Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.29B | 1.51x | 1.61x | 1.83x | 1.99x |
| Medline Inc. (MDLN)vs › | $30.96B | 1.04x | 1.17x | 1.17x | 1.17x |
| Biogen Inc. (BIIB)vs › | $29.53B | 1.11x | 0.96x | 1.19x | 1.43x |
| DexCom, Inc. (DXCM)vs › | $29.08B | 4.51x | 4.22x | 5.88x | 7.46x |
| Centene Corporation (CNC)vs › | $32.19B | 0.34x | 0.25x | 0.39x | 0.51x |
| Zoetis Inc. (ZTS)vs › | $33.36B | 2.70x | 4.24x | 5.43x | 5.83x |
| Veeva Systems Inc. (VEEV)vs › | $25.92B | 2.70x | 4.61x | 5.32x | 6.97x |
| Agilent Technologies, Inc. (A)vs › | $36.67B | 2.94x | 3.06x | 3.38x | 3.71x |
| Waters Corporation (WAT)vs › | $23.17B | 1.40x | 4.10x | 4.54x | 5.46x |
| United Therapeutics Corporation (UTHR)vs › | $23.17B | 3.68x | 2.69x | 2.17x | 2.06x |
IQVIA Holdings Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
- The EV/Assets ratio for IQV stock is 1.51x.
- Is IQVIA Holdings Inc.'s EV/Assets ratio high or low?
- IQVIA Holdings Inc.'s EV/Assets ratio of 1.51x is 24% below its 5-year average of 1.99x, near the low end of its 5-year range (1.36x–2.76x).
- What is the TTM average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average EV/Assets ratio for IQV stock is 1.61x.
- What is the 3Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average EV/Assets ratio for IQV stock is 1.83x.
- What is the 5Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average EV/Assets ratio for IQV stock is 1.99x.
- What is the 10Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average EV/Assets ratio for IQV stock is 1.87x.
IQVIA Holdings Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-12 | 1.51x |
| 2026-06-11 | 1.51x |
| 2026-06-10 | 1.52x |
| 2026-06-09 | 1.54x |
| 2026-06-08 | 1.53x |
| 2026-06-05 | 1.53x |
| 2026-06-04 | 1.55x |
| 2026-06-03 | 1.52x |
| 2026-06-02 | 1.51x |
| 2026-06-01 | 1.54x |
| 2026-05-29 | 1.52x |
| 2026-05-28 | 1.51x |
| 2026-05-27 | 1.42x |
| 2026-05-26 | 1.40x |
| 2026-05-22 | 1.44x |
| 2026-05-21 | 1.44x |
| 2026-05-20 | 1.46x |
| 2026-05-19 | 1.47x |
| 2026-05-18 | 1.46x |
| 2026-05-15 | 1.44x |
| 2026-05-14 | 1.45x |
| 2026-05-13 | 1.46x |
| 2026-05-12 | 1.48x |
| 2026-05-11 | 1.47x |
| 2026-05-08 | 1.50x |
| 2026-05-07 | 1.50x |
| 2026-05-06 | 1.49x |
| 2026-05-05 | 1.49x |
| 2026-05-04 | 1.40x |
| 2026-05-01 | 1.38x |
| 2026-04-30 | 1.38x |
| 2026-04-29 | 1.37x |
| 2026-04-28 | 1.39x |
| 2026-04-27 | 1.41x |
| 2026-04-24 | 1.41x |
| 2026-04-23 | 1.40x |
| 2026-04-22 | 1.48x |
| 2026-04-21 | 1.48x |
| 2026-04-20 | 1.49x |
| 2026-04-17 | 1.49x |
| 2026-04-16 | 1.46x |
| 2026-04-15 | 1.50x |
| 2026-04-14 | 1.48x |
| 2026-04-13 | 1.46x |
| 2026-04-10 | 1.43x |
| 2026-04-09 | 1.44x |
| 2026-04-08 | 1.46x |
| 2026-04-07 | 1.45x |
| 2026-04-06 | 1.45x |
| 2026-04-02 | 1.47x |
| 2026-04-01 | 1.46x |
| 2026-03-31 | 1.45x |
| 2026-03-30 | 1.43x |
| 2026-03-27 | 1.41x |
| 2026-03-26 | 1.45x |
| 2026-03-25 | 1.42x |
| 2026-03-24 | 1.43x |
| 2026-03-23 | 1.43x |
| 2026-03-20 | 1.43x |
| 2026-03-19 | 1.43x |
| 2026-03-18 | 1.43x |
| 2026-03-17 | 1.44x |
| 2026-03-16 | 1.42x |
| 2026-03-13 | 1.42x |
| 2026-03-12 | 1.41x |
| 2026-03-11 | 1.46x |
| 2026-03-10 | 1.46x |
| 2026-03-09 | 1.50x |
| 2026-03-06 | 1.48x |
| 2026-03-05 | 1.50x |
| 2026-03-04 | 1.50x |
| 2026-03-03 | 1.47x |
| 2026-03-02 | 1.47x |
| 2026-02-27 | 1.50x |
| 2026-02-26 | 1.45x |
| 2026-02-25 | 1.40x |
| 2026-02-24 | 1.42x |
| 2026-02-23 | 1.41x |
| 2026-02-20 | 1.42x |
| 2026-02-19 | 1.45x |
| 2026-02-18 | 1.46x |
| 2026-02-17 | 1.42x |
| 2026-02-13 | 1.46x |
| 2026-02-12 | 1.47x |
| 2026-02-11 | 1.52x |
| 2026-02-10 | 1.56x |
| 2026-02-09 | 1.62x |
| 2026-02-06 | 1.59x |
| 2026-02-05 | 1.55x |
| 2026-02-04 | 1.68x |
| 2026-02-03 | 1.68x |
| 2026-02-02 | 1.85x |
| 2026-01-30 | 1.84x |
| 2026-01-29 | 1.87x |
| 2026-01-28 | 1.90x |
| 2026-01-27 | 1.91x |
| 2026-01-26 | 1.90x |
| 2026-01-23 | 1.87x |
| 2026-01-22 | 1.89x |
| 2026-01-21 | 1.91x |
| 2026-01-20 | 1.86x |
| 2026-01-16 | 1.89x |
| 2026-01-15 | 1.91x |
| 2026-01-14 | 1.91x |
| 2026-01-13 | 1.91x |
| 2026-01-12 | 1.91x |
| 2026-01-09 | 1.91x |
| 2026-01-08 | 1.92x |
| 2026-01-07 | 1.93x |
| 2026-01-06 | 1.90x |
| 2026-01-05 | 1.87x |
| 2026-01-02 | 1.81x |
| 2025-12-31 | 1.81x |
| 2025-12-30 | 1.83x |
| 2025-12-29 | 1.82x |
| 2025-12-26 | 1.82x |
| 2025-12-24 | 1.82x |
| 2025-12-23 | 1.81x |
| 2025-12-22 | 1.81x |
| 2025-12-19 | 1.78x |
| 2025-12-18 | 1.80x |
| 2025-12-17 | 1.79x |
| 2025-12-16 | 1.79x |
| 2025-12-15 | 1.80x |
| 2025-12-12 | 1.79x |
| 2025-12-11 | 1.82x |
| 2025-12-10 | 1.80x |
| 2025-12-09 | 1.77x |
| 2025-12-08 | 1.80x |
| 2025-12-05 | 1.82x |
| 2025-12-04 | 1.81x |
| 2025-12-03 | 1.82x |
| 2025-12-02 | 1.81x |
| 2025-12-01 | 1.83x |
| 2025-11-28 | 1.84x |
| 2025-11-26 | 1.85x |
| 2025-11-25 | 1.85x |
| 2025-11-24 | 1.83x |
| 2025-11-21 | 1.81x |
| 2025-11-20 | 1.76x |
| 2025-11-19 | 1.77x |
| 2025-11-18 | 1.76x |
| 2025-11-17 | 1.76x |
| 2025-11-14 | 1.78x |
| 2025-11-13 | 1.80x |
| 2025-11-12 | 1.79x |
| 2025-11-11 | 1.77x |
| 2025-11-10 | 1.74x |
| 2025-11-07 | 1.72x |
| 2025-11-06 | 1.73x |
| 2025-11-05 | 1.72x |
| 2025-11-04 | 1.73x |
| 2025-11-03 | 1.74x |
| 2025-10-31 | 1.76x |
| 2025-10-30 | 1.76x |
| 2025-10-29 | 1.77x |
| 2025-10-28 | 1.77x |
| 2025-10-27 | 1.79x |
| 2025-10-24 | 1.81x |
| 2025-10-23 | 1.81x |
| 2025-10-22 | 1.79x |
| 2025-10-21 | 1.80x |
| 2025-10-20 | 1.76x |
| 2025-10-17 | 1.71x |
| 2025-10-16 | 1.72x |
| 2025-10-15 | 1.71x |
| 2025-10-14 | 1.72x |
| 2025-10-13 | 1.71x |
| 2025-10-10 | 1.68x |
| 2025-10-09 | 1.71x |
| 2025-10-08 | 1.69x |
| 2025-10-07 | 1.69x |
| 2025-10-06 | 1.72x |
| 2025-10-03 | 1.73x |
| 2025-10-02 | 1.71x |
| 2025-10-01 | 1.71x |
| 2025-09-30 | 1.63x |
| 2025-09-29 | 1.57x |
| 2025-09-26 | 1.56x |
| 2025-09-25 | 1.55x |
| 2025-09-24 | 1.57x |
| 2025-09-23 | 1.60x |
| 2025-09-22 | 1.61x |
| 2025-09-19 | 1.61x |
| 2025-09-18 | 1.63x |
| 2025-09-17 | 1.61x |
| 2025-09-16 | 1.61x |
| 2025-09-15 | 1.60x |
| 2025-09-12 | 1.61x |
| 2025-09-11 | 1.63x |
| 2025-09-10 | 1.59x |
| 2025-09-09 | 1.62x |
| 2025-09-08 | 1.61x |
| 2025-09-05 | 1.61x |
| 2025-09-04 | 1.59x |
| 2025-09-03 | 1.59x |
| 2025-09-02 | 1.59x |
| 2025-08-29 | 1.63x |
| 2025-08-28 | 1.62x |
| 2025-08-27 | 1.62x |
| 2025-08-26 | 1.61x |
| 2025-08-25 | 1.61x |
| 2025-08-22 | 1.63x |
| 2025-08-21 | 1.60x |
| 2025-08-20 | 1.64x |
| 2025-08-19 | 1.64x |
| 2025-08-18 | 1.64x |
| 2025-08-15 | 1.63x |
| 2025-08-14 | 1.62x |
| 2025-08-13 | 1.63x |
| 2025-08-12 | 1.60x |
| 2025-08-11 | 1.57x |
| 2025-08-08 | 1.57x |
| 2025-08-07 | 1.56x |
| 2025-08-06 | 1.55x |
| 2025-08-05 | 1.59x |
| 2025-08-04 | 1.58x |
| 2025-08-01 | 1.58x |
| 2025-07-31 | 1.60x |
| 2025-07-30 | 1.64x |
| 2025-07-29 | 1.65x |
| 2025-07-28 | 1.67x |
| 2025-07-25 | 1.68x |
| 2025-07-24 | 1.69x |
| 2025-07-23 | 1.65x |
| 2025-07-22 | 1.61x |
| 2025-07-21 | 1.50x |
| 2025-07-18 | 1.51x |
| 2025-07-17 | 1.53x |
| 2025-07-16 | 1.50x |
| 2025-07-15 | 1.49x |
| 2025-07-14 | 1.51x |
| 2025-07-11 | 1.52x |
| 2025-07-10 | 1.54x |
| 2025-07-09 | 1.52x |
| 2025-07-08 | 1.54x |
| 2025-07-07 | 1.52x |
| 2025-07-03 | 1.53x |
| 2025-07-02 | 1.54x |
| 2025-07-01 | 1.52x |
| 2025-06-30 | 1.49x |
| 2025-06-27 | 1.49x |
| 2025-06-26 | 1.49x |
| 2025-06-25 | 1.50x |
| 2025-06-24 | 1.50x |
| 2025-06-23 | 1.47x |
| 2025-06-20 | 1.47x |
| 2025-06-18 | 1.47x |
| 2025-06-17 | 1.47x |
| 2025-06-16 | 1.50x |
| 2025-06-13 | 1.49x |
| 2025-06-12 | 1.50x |
| 2025-06-11 | 1.50x |
| 2025-06-10 | 1.50x |
| 2025-06-09 | 1.47x |
| 2025-06-06 | 1.46x |
| 2025-06-05 | 1.42x |
| 2025-06-04 | 1.43x |
| 2025-06-03 | 1.39x |
| 2025-06-02 | 1.37x |
Showing the most recent 260 of 3,172 data points. The chart above shows the full history.
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib